How does cosentyx's long term safety compare with similar drugs?

What does Cosentyx (secukinumab) show on long-term safety?

Cosentyx (secukinumab) is used for plaque psoriasis and related inflammatory conditions. Long-term safety for secukinumab has been followed through multi-year clinical follow-up and safety monitoring programs, with the overall finding that adverse events seen over time generally stay consistent with what was observed earlier in treatment (meaning no new major safety signal has emerged in longer follow-up studies) [1].

The long-term safety profile is also characterized by known class effects typical of IL‑17 pathway inhibition, such as:

- Infection risk consistent with immunomodulatory therapies, particularly upper respiratory infections and, in some studies, more frequent candidiasis events [1].
- Safety outcomes including serious adverse events and discontinuations tracked over time, with rates reported as comparable to expectations for this treatment class in long-term follow-up datasets [1].

Because your question asks for comparison, it’s important to compare secukinumab against other biologics that treat similar diseases using either the same pathway (IL‑17 inhibitors) or different targets (TNF inhibitors, IL‑23 inhibitors, etc.).

How does Cosentyx compare with other IL-17 inhibitors over the long term?

Direct “apples-to-apples” long-term comparisons across drugs are limited because trials differ in populations, dosing, background therapies, study duration, and how events are captured. Still, among IL‑17 inhibitors, the key long-term safety themes tend to overlap: infection-related events (including mucocutaneous fungal infections like Candida) and the absence of a pattern of unexpected late-emerging toxicities in long-term extensions [1].

So, if you’re comparing Cosentyx to other IL‑17 drugs (such as brodalumab or ixekizumab), the long-term safety story is usually similar in kind, with differences more likely to show up in the frequency of certain event types (for example, candidiasis) rather than in wholly new categories of harm. The most meaningful comparison comes from head-to-head or pooled real-world analyses, but those depend on which drugs and which indication you care about.

How does Cosentyx compare with TNF blockers on long-term safety?

TNF inhibitors are another major class used for overlapping inflammatory diseases. Compared with IL‑17 blockade, TNF inhibitors have long-term safety considerations that often include higher emphasis on:

- Serious infections and reactivation risk patterns associated with TNF suppression (depending on the specific TNF agent and patient risk profile).
- Differences in how malignancy risk signals are interpreted over time (because absolute risks are low and confounded by disease severity) [1].

In contrast, IL‑17 inhibitors (like secukinumab) tend to focus long-term safety messaging on class effects such as fungal infections and the broader immunomodulation-related infection profile, rather than the same reactivation concerns that are traditionally highlighted for TNF inhibitors [1].

How does Cosentyx compare with IL-23 inhibitors on long-term safety?

IL‑23 inhibitors (used for psoriasis and other immune-driven conditions) are generally considered to have a long-term safety profile that is also consistent and has been monitored for multi-year outcomes, but they target a different part of the immune pathway than IL‑17 inhibitors. The safety “shape” across biologics is therefore not identical.

In general terms, IL‑23 blockade is associated with its own class-specific risks and monitoring considerations, while IL‑17 blockade emphasizes infection and mucocutaneous fungal events as recurring themes in long-term follow-up [1]. For psoriasis specifically, long-term comparative safety is best judged using multi-year registries and real-world evidence alongside trial extensions.

What safety risks do patients most often ask about long term?

Patients and clinicians typically focus on these long-term issues when comparing Cosentyx with similar biologics:

- Serious infections: how often they occur during long-term exposure and which patient factors raise risk.
- Opportunistic and fungal infections: particularly Candida-related events, which are a recurring focus for IL‑17 inhibitors [1].
- Malignancy and major cardiovascular events: monitored over time because underlying disease itself raises baseline risk; long-term trial and registry data are used to interpret whether additional risk emerges [1].
- Immunogenicity (anti-drug antibodies) and whether it affects long-term safety or effectiveness; this can differ by drug and formulation and is tracked over multi-year periods [1].

What’s the most reliable way to compare long-term safety between drugs?

For the most credible comparison, look for:

- Multi-year extension results for each drug in the same indication (like psoriasis).
- Registries and real-world studies that follow patients beyond the timeframe of clinical trials.
- Analyses that adjust for baseline risk factors (age, comorbidities, steroid use, prior biologics, infection history).

The reason this matters: long-term safety can look different depending on patient mix (for example, more high-risk patients in one dataset than another), and adverse event capture methods vary.

If you tell me the exact “similar drugs,” I can compare more directly

“Similar drugs” can mean IL‑17 inhibitors, TNF blockers, IL‑23 inhibitors, or even different biologics within the same indication. If you share which drugs you mean (and the condition, like plaque psoriasis vs psoriatic arthritis), I can narrow the comparison to the specific long-term safety outcomes reported for those agents.

Sources:
[1] https://www.cosentyx.com/safety-and-side-effects